This extension study is designed to further evaluate the safety and tolerability of ARQ 197 monotherapy or in combination with other drug(s) when given to patients who tolerated previous treatment well and may benefit from the continuing treatment. ARQ 197 will be administered twice daily, orally, with meals (regardless of the original protocol requirements).